New drugs for CMML: ongoing clinical trials in CMML in 2017
| Tested drug(s) . | Title . | Clinicaltrials.gov . | Phase trial . | Reference . |
|---|---|---|---|---|
| Decitabine | Decitabine ± Hydroxyurea Versus Hydroxyurea in advanced proliferative CMML | NCT02214407 | Phase 3 randomized multicenter | 109 |
| Guadecitabine (SGI-110) | Guadecitabine and Atezolizumab in Patients With Advanced MDS or CMML | NCT02935361 | Phase 1/2 | 124 |
| Guadecitabine (SGI-110) | Guadecitabine (SGI-110) vs Treatment Choice in MDS or CMML treated With HMAs | NCT02907359 | Phase 3, randomized multicenter | 124 |
| Nivolumab and ipilimumab | Nivolumab and ipilimumab with AZA in patients with MDS (may include CMML) | NCT02530463 | Phase 1/2 | 125 |
| AG-120 | AG-120 or AG-221 in patients with Newly Diagnosed AML with an IDH1 and/or IDH2 mutation | NCT02632708 | Phase 1 | 126-128 |
| AG-221 | ||||
| PF-04449913 (glasdegib) | PF-04449913 (Glasdegib) and azacitidine In 1st Line MDS, AML and CMML | NCT02367456 | Phase 1b/2 randomized multicenter | 137 |
| H3B-8800 | Phase 1 of Splicing Modulator H3B-8800 for Subjects With MDS, AML, and CMML | NCT02841540 | Phase 1 | 139,140 |
| Lenzilumab (KB003) | Lenzilumab (KB003) in previously treated patients with CMML | NCT02546284 | Phase 1 | 88 |
| Tipifarnib | Tipifarnib in patients with CMML | NCT02807272 | Phase 2 | 130 |
| SL-401 | SL-401 in advanced, high-risk MPNs and CMML | NCT02268253 | Phase 1/2 | 131 |
| Sotatercept | Sotatercept for Anemia in low- or Intermediate-1 Risk MDS or Non-proliferative CMML | NCT01736683 | Phase 2 randomized | 141 |
| Eltrombopag | Eltrombopag in patients with CMML and thrombocytopenia | NCT02323178 | Phase 1/2 | 62 |
| Pacritinib | Pacritinib with Low Dose Decitabine in Intermediate-High Risk MF or MPN/MDS | NCT02564536 | Pilot study |
| Tested drug(s) . | Title . | Clinicaltrials.gov . | Phase trial . | Reference . |
|---|---|---|---|---|
| Decitabine | Decitabine ± Hydroxyurea Versus Hydroxyurea in advanced proliferative CMML | NCT02214407 | Phase 3 randomized multicenter | 109 |
| Guadecitabine (SGI-110) | Guadecitabine and Atezolizumab in Patients With Advanced MDS or CMML | NCT02935361 | Phase 1/2 | 124 |
| Guadecitabine (SGI-110) | Guadecitabine (SGI-110) vs Treatment Choice in MDS or CMML treated With HMAs | NCT02907359 | Phase 3, randomized multicenter | 124 |
| Nivolumab and ipilimumab | Nivolumab and ipilimumab with AZA in patients with MDS (may include CMML) | NCT02530463 | Phase 1/2 | 125 |
| AG-120 | AG-120 or AG-221 in patients with Newly Diagnosed AML with an IDH1 and/or IDH2 mutation | NCT02632708 | Phase 1 | 126-128 |
| AG-221 | ||||
| PF-04449913 (glasdegib) | PF-04449913 (Glasdegib) and azacitidine In 1st Line MDS, AML and CMML | NCT02367456 | Phase 1b/2 randomized multicenter | 137 |
| H3B-8800 | Phase 1 of Splicing Modulator H3B-8800 for Subjects With MDS, AML, and CMML | NCT02841540 | Phase 1 | 139,140 |
| Lenzilumab (KB003) | Lenzilumab (KB003) in previously treated patients with CMML | NCT02546284 | Phase 1 | 88 |
| Tipifarnib | Tipifarnib in patients with CMML | NCT02807272 | Phase 2 | 130 |
| SL-401 | SL-401 in advanced, high-risk MPNs and CMML | NCT02268253 | Phase 1/2 | 131 |
| Sotatercept | Sotatercept for Anemia in low- or Intermediate-1 Risk MDS or Non-proliferative CMML | NCT01736683 | Phase 2 randomized | 141 |
| Eltrombopag | Eltrombopag in patients with CMML and thrombocytopenia | NCT02323178 | Phase 1/2 | 62 |
| Pacritinib | Pacritinib with Low Dose Decitabine in Intermediate-High Risk MF or MPN/MDS | NCT02564536 | Pilot study |